Trial Profile
A Phase 1, Single-Dose, Open Label, Pharmacokinetic and Pharmacodynamic Study of RDEA3170 in Adult Male Subjects With Mild, Moderate, and Severe Renal Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Verinurad (Primary)
- Indications Gout; Hyperuricaemia
- Focus Pharmacokinetics
- Sponsors Ardea Biosciences
- 11 Jun 2018 Results published in the Clinical Drug Investigation
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
- 30 Aug 2016 Status changed from active, no longer recruiting to completed.